Open AccessIntegrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
Author(s) -
Mark Underwood,
Joe Horton,
Keith Nangle,
Judy Hopking,
Kimberly Y. Smith,
Michael Aboud,
Brian Wynne,
Jörg Sievers,
Eugene L. Stewart,
Ruolan Wang
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01643-21
Subject(s) - dolutegravir , integrase , integrase inhibitor , virology , raltegravir , elvitegravir , nucleoside reverse transcriptase inhibitor , drug resistance , medicine , biology , pharmacology , viral load , human immunodeficiency virus (hiv) , genetics , antiretroviral therapy
At week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI) dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to ritonavir-boosted lopinavir in achieving virologic suppression in adults with HIV-1 who failed first-line therapy. Here, we report emergent HIV-1 drug resistance and mechanistic underpinnings among dolutegravir-treated adults in DAWNING.